

EFNA1 Antibody

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP50678

Specification

EFNA1 Antibody - Product Information

Application IF, WB
Primary Accession P20827
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Calculated MW 24 21 KDa
Antigen Region 83-115

EFNA1 Antibody - Additional Information

Gene ID 1942

Other Names

Ephrin-A1, EPH-related receptor tyrosine kinase ligand 1, LERK-1, Immediate early response protein B61, Tumor necrosis factor alpha-induced protein 4, TNF alpha-induced protein 4, Ephrin-A1, secreted form, EFNA1, EPLG1, LERK1, TNFAIP4

Dilution

IF~~1:100 WB~~1:1000

Format

Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.09% (W/V) sodium azide and 50% glycerol.

Storage Conditions

-20°C

EFNA1 Antibody - Protein Information

Name EFNA1

Synonyms EPLG1, LERK1, TNFAIP4

Function

Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. Plays an important role in angiogenesis and tumor neovascularization. The recruitment of VAV2, VAV3 and PI3-kinase p85 subunit by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly. Exerts anti-oncogenic effects in tumor cells



through activation and down- regulation of EPHA2. Activates EPHA2 by inducing tyrosine phosphorylation which leads to its internalization and degradation. Acts as a negative regulator in the tumorigenesis of gliomas by down- regulating EPHA2 and FAK. Can evoke collapse of embryonic neuronal growth cone and regulates dendritic spine morphogenesis.

Cellular Location

Cell membrane; Lipid-anchor, GPI-anchor

Tissue Location


Brain. Down-regulated in primary glioma tissues compared to the normal tissues. The soluble monomeric form is expressed in the glioblastoma multiforme (GBM) and breast cancer cells (at protein level).

EFNA1 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

EFNA1 Antibody - Images



Immunofluorescence analysis of HeLa cells, using EFNA1 antibody.





Western blot analysis of lysate from MCF7 cell line, using EFNA1 Antibody(AP50678). AP50678 was diluted at 1:1000. A goat anti-rabbit IgG H&L(HRP) at 1:5000 dilution was used as the secondary antibody. Lysate at 35ug.

EFNA1 Antibody - Background

Cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. Binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. Plays an important role in angiogenesis and tumor neovascularization. The recruitment of VAV2, VAV3 and PI3-kinase p85 subunit by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly. Exerts anti-oncogenic effects in tumor cells through activation and down-regulation of EPHA2. Activates EPHA2 by inducing tyrosine phosphorylation which leads to its internalization and degradation. Acts as a negative regulator in the tumorigenesis of gliomas by down-regulating EPHA2 and FAK. Can evoke collapse of embryonic neuronal growth cone and regulates dendritic spine morphogenesis.

EFNA1 Antibody - References

Holzman L.B.,et al.Mol. Cell. Biol. 10:5830-5838(1990). Ebert L.,et al.Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases. Gregory S.G.,et al.Nature 441:315-321(2006). Mural R.J.,et al.Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases. Zhang Z.,et al.Protein Sci. 13:2819-2824(2004).